// App-Quantinova.ai

P035 : Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)

Researchers

Presenter

  • P. Vermersch

Principal Investigators

  • J. Erlinna

  • R. Nicholas

  • C. Oreja-Guevara

  • A. Siva

  • B. Van Wijmeersch

  • H. Wiendl

  • R. Buffels

  • W. Wei

  • G. Comi

Medical Centers

  • University Hospital of Lille, Lille, France

  • NEO Research, Turku, Finland

  • Imperial College Healthcare NHS Trust, Radiology, London, United Kingdom

  • Hospital Clinico San Carlos, IBD Unit, Madrid, Spain

  • Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

  • University Hasselt and Rehabilitation & MS-Centre, Overpelt, Belgium

  • University Hospital of Muenster, Muenster, Germany

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Vita-Salute San Raffaele University, Milan, Italy

Locations

  • France

  • Finland

  • United Kingdom

  • Spain

  • Turkey

  • Belgium

  • Germany

  • Switzerland

  • Italy

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Ocrelizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02861014

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved